Entity family
Organisations named as supporting, sponsoring, or funding research. Examples include Wellcome, NIHR, research councils.
Showing 541–600 of 3,238, ordered by supporting articles. Choose a funder to see its evidence.
…e liver disease (ESLD) and hepatocellular carcinoma (HCC) 1.The World Health Organization aims to reduce HBV incidence by 95% and HBV-related mortality b…
…ogy input.References Liver disease profile, April 2024 update – GOV.UK – accessed 01/06/2025.Exploring local income deprivation.…
…ns.Reference World Health Organization. Hepatitis B [Internet]. World Health Organization. 2024. Available from: https://www.who.int/news-room/fact-sheet…
…tion. Patients are provided with information resources from the British Liver Trust.A decision is made on the day as to whether the patient can be …
…Background and Aims MAESTRO-NASH Outcomes ( NCT05500222) is a multi-national, multicenter, double-blind, randomized, pl…
… between March-June 2024 to participate in a CBPAP supported by local government. Patients selected at random were offered enrolment to a free s…
… are unaware of its purpose and are disengaged from their care. NHS England has identified HCC as a priority cancer for early diagnosis, hi…
…from May 2021 to June 2025.Patient selection for SCA adhered to NICE guidance.Since launch, the tool enabled referrals for 100% (150…
…s with newly diagnosed chronic HBV from ED testing at two large NHS Trusts in Southeast London in the first 20 months of testing.Method Pa…
…ma (HCC), despite achieving sustained virologic response (SVR). EASL issued a position paper in 2024 on follow-up following successf…
…idelines.Methods We conducted a retrospective cohort study at a West London NHS Trust and analysed the 5-year clinical outcomes of hepatitis B e-anti…
…ation.Patients in this study (n = 150) were enrolled in MYR301 (NCT03852719), a Phase 3, randomised (1:1:1), multicentre, open-label, paral…